Opus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ETUpcoming Data Readout for Cohort 1 of OPGx-BEST1 ...

Detailed price information for Opus Genetics Inc (IRD-Q) from The Globe and Mail including charting and trades.

Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of ...

India carries one of the world's largest thalassemia burdens, with nearly 35 to 45 million carriers of the beta thalassemia ...

Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 - All pre-spec ...

Completed transformative acquisition of PXL-770, (now SCY-770), an innovative, highly selective, direct AMPK activator for the treatment of autosomal dominant polycystic kidney disease (ADPKD)A Phase ...

A team led by USC Stem Cell scientist Zhongwei Li, PhD, has produced some of the most complex and mature lab-grown kidney ...

Explore the urgent need to shift thalassemia care in India from management to prevention through carrier screening and ...

Red hair has always had a way of standing out. It catches the light, changes from copper to auburn to strawberry blond depending on the room, and tends to make people look twice. It’s something that ...

Atrium Therapeutics, Inc. ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today ...

Bristol's partnership with Hengrui Pharma, Viiv loses HIV treatment case, and more biotech news from The Readout ...